[17]Updated analysis of DESTINY-Gastric02:A phase II single-arm trial of trastuzumab deruxtecan(T-DXd)in western patients(Pts)with HER2-positive(HER2+)unresectable/metastatic gastric/gastroesophageal junction(GEJ)cancer who progressed on or after trastuzumab-containing regimen.2022 ESMO 1205MO. [18]...
If yourbreast cancerhas a significant number of receptors for either estrogen or progesterone, it’s considered hormone-receptor positive. Tumors that are ER/PR-positive are much more likely to respond to hormone therapy than tumors that are ER/PR-negative. ...
[3]Curigliano G., et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (...
13、Hua, Xin et al. Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002). Clinical cancer research : an official journal of the Am...
[17]Updated analysis of DESTINY-Gastric02:A phase II single-arm trial of trastuzumab deruxtecan(T-DXd)in western patients(Pts)with HER2-positive(HER2+)unresectable/metastatic gastric/gastroesophageal junction(GEJ)cancer who progressed on or after trastuzumab-containing regimen.2022 ESMO 1205MO. ...
参考文献: Marra, Antonio et al. “Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives.” Nature reviews. Clinical oncology vol. 21,3 (2024): 185-202. doi:10.1038/s41571-023-00849-9...
[9]van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a s...
Variety of Adjuvant Strategies Explored in HER2‑Positive and Other Breast Cancer TypesCharlotte Bath
Approximately one in five breast cancers are driven by amplification and overexpression of the human epidermal growth factor receptor 2 (HER2) receptor kinase, and HER2-enriched (HER2E) is one of four major transcriptional subtypes of breast cancer. We s
[16] Ana Christina Garrido-Castro et al., SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.. JCO 42, LBA1004-LBA1004(2024). ...